Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Ben Soffer, aka @boywithnojob, discusses his journey from social media influencer to entrepreneur and why he wanted to enter the competitive drink space. Watch!
StockstoTrade.com Technical Trainer, Tim Bohen, discusses why he thinks Trump is doing what he is doing and how it will affect the market going forward.
Jacob Sonenshine, Stock Pick Writer at Barron's, unpacks the current state of the markets, Trump's tariffs and if more volatility is on the way. Watch!
RedFin's Chen Zhao joins Cheddar to breakdown the current state of the housing market in the United States and what prospective homebuyers need to know. Watch!
